CHRS - Coherus BioSciences Stock Price, News & Analysis

$9.35 0.30 (3.31 %)
(As of 11/23/2017 04:00 PM ET)
Previous Close$9.05
Today's Range$8.95 - $9.55
52-Week Range$8.05 - $29.59
Volume440,900 shs
Average Volume606,450 shs
Market Capitalization$541.79 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Coherus BioSciences (NASDAQ:CHRS)

Coherus BioSciences logoCoherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company's product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214.


Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:CHRS
CUSIPN/A

Debt

Debt-to-Equity Ratio1.84%
Current Ratio5.46%
Quick Ratio5.46%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$190.11 million
Price / Sales2.85
Cash FlowN/A
Price / CashN/A
Book Value$0.95 per share
Price / Book9.84

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($5.42)
Net Income$-127,330,000.00
Net Margins-73.89%
Return on Equity-582.31%
Return on Assets-138.04%

Miscellaneous

Employees152
Outstanding Shares57,940,000

Frequently Asked Questions for Coherus BioSciences (NASDAQ:CHRS)

What is Coherus BioSciences' stock symbol?

Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."

How were Coherus BioSciences' earnings last quarter?

Coherus BioSciences, Inc. (NASDAQ:CHRS) posted its earnings results on Monday, November, 6th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by $0.26. Coherus BioSciences had a negative return on equity of 582.31% and a negative net margin of 73.89%. View Coherus BioSciences' Earnings History.

Where is Coherus BioSciences' stock going? Where will Coherus BioSciences' stock price be in 2017?

9 equities research analysts have issued twelve-month price targets for Coherus BioSciences' stock. Their predictions range from $17.00 to $46.00. On average, they expect Coherus BioSciences' share price to reach $32.89 in the next year. View Analyst Ratings for Coherus BioSciences.

What are Wall Street analysts saying about Coherus BioSciences stock?

Here are some recent quotes from research analysts about Coherus BioSciences stock:

  • 1. According to Zacks Investment Research, "Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California. " (10/10/2017)
  • 2. Maxim Group analysts commented, "The challenge for biosimilar makers of humira is not similar efficacy, it’s winning the IP battle with AbbVie. Coherus, in our view, was ideally positioned to win the biosimilar race as it was founded with a focus on IP." (9/8/2017)
  • 3. Credit Suisse Group analysts commented, "We are raising our PT from $35 to $40 post 4Q16. We arrive at our PT by using a DCF analysis. Post the quarter, we continue to believe that upwards earnings revisions to levels not yet reflected in sell-side expectations should drive ACRS shares higher. We believe upwards consensus earnings revisions could come from: 1) Faster than expected uptake and higher than expected peak sales of A-101 for SK; 2) Commercialization of A-101 for common warts; and, 3) Free call options on ATI-50001, ATI-50002, and other early stage pipeline opportunities. Positives from the 4Q16 release that support our thesis: 1) In November of ’16, ACRS reported that two pivotal Phase 3 trials of its lead product candidate A-101 40% Topical Solution met all primary and secondary endpoints of each trial, achieving clinically and statistically significant clearance of seborrheic keratosis (SK) lesions. In February 2017, ACRS submitted a New Drug Application NDA for A-101 40% Topical Solution for the treatment of SK to the FDA. 2) During ’16 ACRS also reported positive data from a Phase 2 trial of A-101 45% Topical Solution for the treatment of common warts. 3) ACRS recently completed a Phase 1 clinical trial of ATI-50001, its investigational JAK inhibitor, for the treatment of alopecia totalis and alopecia universalis. And, 4) ACRS had cash and cash equivalents of $174.1MM as of 12/31/16." (3/16/2017)

Who are some of Coherus BioSciences' key competitors?

Who are Coherus BioSciences' key executives?

Coherus BioSciences' management team includes the folowing people:

  • Dennis M. Lanfear, Chairman of the Board, President, Chief Executive Officer (Age 61)
  • Jean-Frederic Viret Ph.D., Chief Financial Officer (Age 51)
  • Peter K. Watler, Chief Technology Officer (Age 55)
  • Alan C. Herman Ph.D., Chief Scientific Officer (Age 69)
  • Barbara K. Finck M.D., Chief Medical Officer (Age 69)
  • Mats Wahlstrom, Lead Independent Director (Age 63)
  • Christos Richards, Director (Age 59)
  • August J. Troendle M.D., Director (Age 60)
  • James I. Healy M.D. Ph.D., Independent Director (Age 52)
  • V. Bryan Lawlis Jr. Ph.D., Independent Director (Age 65)

Who owns Coherus BioSciences stock?

Coherus BioSciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Temasek Holdings Private Ltd (11.32%), Brown Advisory Inc. (1.03%), Alyeska Investment Group L.P. (0.97%), State of Wisconsin Investment Board (1.05%), Ameriprise Financial Inc. (0.63%) and Macquarie Group Ltd. (0.50%). Company insiders that own Coherus BioSciences stock include Alan C Herman, Dennis M Lanfear, Fmr Llc, Jean-Frederic Viret, Mats Wahlstrom and Peter K Watler. View Institutional Ownership Trends for Coherus BioSciences.

Who sold Coherus BioSciences stock? Who is selling Coherus BioSciences stock?

Coherus BioSciences' stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Citadel Advisors LLC, Alyeska Investment Group L.P., Macquarie Group Ltd., Highbridge Capital Management LLC and California State Teachers Retirement System. Company insiders that have sold Coherus BioSciences company stock in the last year include Alan C Herman, Jean-Frederic Viret and Mats Wahlstrom. View Insider Buying and Selling for Coherus BioSciences.

Who bought Coherus BioSciences stock? Who is buying Coherus BioSciences stock?

Coherus BioSciences' stock was acquired by a variety of institutional investors in the last quarter, including Temasek Holdings Private Ltd, State of Wisconsin Investment Board, Teachers Retirement System of The State of Kentucky, Wells Fargo & Company MN, Platinum Investment Management Ltd., Pictet Asset Management Ltd., Brown Advisory Inc. and Handelsbanken Fonder AB. View Insider Buying and Selling for Coherus BioSciences.

How do I buy Coherus BioSciences stock?

Shares of Coherus BioSciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Coherus BioSciences' stock price today?

One share of Coherus BioSciences stock can currently be purchased for approximately $9.35.

How big of a company is Coherus BioSciences?

Coherus BioSciences has a market capitalization of $541.79 million and generates $190.11 million in revenue each year. The biotechnology company earns $-127,330,000.00 in net income (profit) each year or ($5.42) on an earnings per share basis. Coherus BioSciences employs 152 workers across the globe.

How can I contact Coherus BioSciences?

Coherus BioSciences' mailing address is 333 Twin Dolphin Dr Ste 600, REDWOOD CITY, CA 94065-1442, United States. The biotechnology company can be reached via phone at +1-650-6493530 or via email at [email protected]


MarketBeat Community Rating for Coherus BioSciences (CHRS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  160 (Vote Outperform)
Underperform Votes:  121 (Vote Underperform)
Total Votes:  281
MarketBeat's community ratings are surveys of what our community members think about Coherus BioSciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Coherus BioSciences (NASDAQ:CHRS)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 9 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $32.89 (251.75% upside)

Consensus Price Target History for Coherus BioSciences (NASDAQ:CHRS)

Price Target History for Coherus BioSciences (NASDAQ:CHRS)

Analysts' Ratings History for Coherus BioSciences (NASDAQ:CHRS)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/7/2017Citigroup Inc.Reiterated RatingBuy$23.00N/AView Rating Details
9/27/2017Credit Suisse GroupReiterated RatingOutperform$24.00 -> $17.00LowView Rating Details
9/8/2017Cowen and CompanyReiterated RatingOutperform$45.00LowView Rating Details
9/8/2017Maxim GroupReiterated RatingBuy$40.00 -> $20.00HighView Rating Details
8/8/2017J P Morgan Chase & CoReiterated RatingOverweight -> Overweight$32.00 -> $25.00LowView Rating Details
6/13/2017BMO Capital MarketsLower Price TargetOutperform$54.00 -> $43.00HighView Rating Details
6/13/2017Robert W. BairdLower Price TargetOutperform$40.00 -> $37.00HighView Rating Details
5/21/2017Barclays PLCReiterated RatingOverweight$46.00HighView Rating Details
11/25/2016Standpoint ResearchInitiated CoverageBuy$40.00N/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for Coherus BioSciences (NASDAQ:CHRS)

Earnings by Quarter for Coherus BioSciences (NASDAQ:CHRS)

Earnings History by Quarter for Coherus BioSciences (NASDAQ CHRS)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017Q3 2017($0.83)($1.09)ViewN/AView Earnings Details
8/7/2017Q2 2017($1.29)($1.08)$1.40 millionViewListenView Earnings Details
5/8/2017Q1 2017($1.54)($1.54)$0.16 millionViewListenView Earnings Details
3/13/2017Q4 2016($1.11)($1.71)$10.00 million$0.84 millionViewListenView Earnings Details
11/9/2016Q3 2016($1.56)$1.67$7.20 million$162.80 millionViewListenView Earnings Details
8/9/2016Q2($1.32)($1.72)$6.87 million$14.07 millionViewListenView Earnings Details
5/9/2016Q1($1.42)($1.67)$12.36 millionViewListenView Earnings Details
2/29/2016Q4($1.74)($1.35)$8.63 million$10.20 millionViewListenView Earnings Details
11/9/2015Q3($1.86)$16.10 million$7.20 millionViewListenView Earnings Details
8/10/2015Q215($1.56)$488.15 million$6.87 millionViewListenView Earnings Details
5/11/2015Q115($1.22)$488.15 million$5.81 millionViewListenView Earnings Details
3/23/2015Q414($0.46)($1.47)$6.50 millionViewListenView Earnings Details
12/15/2014Q212($1.79)$16.10 millionViewN/AView Earnings Details
3/27/2012($0.02)($0.06)ViewN/AView Earnings Details
12/1/2011($0.09)($0.08)ViewN/AView Earnings Details
9/1/2011$0.01($0.01)ViewN/AView Earnings Details
6/2/2011$0.12$0.17ViewN/AView Earnings Details
3/24/2011($0.19)($0.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Coherus BioSciences (NASDAQ:CHRS)
Current Year EPS Consensus Estimate: $-4.39 EPS
Next Year EPS Consensus Estimate: $-2.9 EPS

Dividends

Dividend History for Coherus BioSciences (NASDAQ:CHRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Coherus BioSciences (NASDAQ CHRS)

Insider Ownership Percentage: 26.28%
Institutional Ownership Percentage: 72.18%
Insider Trades by Quarter for Coherus BioSciences (NASDAQ:CHRS)
Institutional Ownership by Quarter for Coherus BioSciences (NASDAQ:CHRS)

Insider Trades by Quarter for Coherus BioSciences (NASDAQ CHRS)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/8/2017Alan C HermanInsiderSell17,535$15.02$263,375.70View SEC Filing  
7/5/2017Alan C HermanInsiderSell600$15.00$9,000.00View SEC Filing  
4/3/2017Alan C HermanInsiderSell11,333$20.73$234,933.09View SEC Filing  
1/25/2017Jean-Frederic ViretCFOSell3,900$27.00$105,300.00View SEC Filing  
12/16/2016Jean-Frederic ViretCFOSell3,900$28.30$110,370.00View SEC Filing  
12/8/2016Mats WahlstromDirectorSell53,583$27.52$1,474,604.16View SEC Filing  
12/1/2016Alan C HermanInsiderSell11,333$27.40$310,524.20View SEC Filing  
10/21/2016Jean-Frederic ViretCFOSell3,900$30.62$119,418.00View SEC Filing  
10/3/2016Alan C HermanInsiderSell11,333$25.69$291,144.77View SEC Filing  
9/26/2016Jean-Frederic ViretCFOSell3,900$29.88$116,532.00View SEC Filing  
9/21/2016Dennis M LanfearInsiderSell4,060$31.75$128,905.00View SEC Filing  
9/16/2016Dennis M LanfearInsiderSell2,900$31.79$92,191.00View SEC Filing  
8/8/2016Fmr LlcInsiderSell100,000$29.86$2,986,000.00View SEC Filing  
8/5/2016Fmr LlcInsiderSell48,600$28.48$1,384,128.00View SEC Filing  
8/1/2016Alan C HermanInsiderSell11,333$25.54$289,444.82View SEC Filing  
7/21/2016Peter K WatlerInsiderSell3,991$26.13$104,284.83View SEC Filing  
7/20/2016Peter K WatlerInsiderSell73,741$25.02$1,844,999.82View SEC Filing  
7/11/2016Peter K WatlerInsiderSell43,495$20.02$870,769.90View SEC Filing  
7/1/2016Alan C HermanInsiderSell4,250$16.89$71,782.50View SEC Filing  
6/1/2016Alan C HermanInsiderSell4,250$18.67$79,347.50View SEC Filing  
5/17/2016Peter K WatlerInsiderSell12,000$20.00$240,000.00View SEC Filing  
5/2/2016Alan C HermanInsiderSell4,250$19.20$81,600.00View SEC Filing  
2/5/2016Alan C HermanInsiderSell2,000$15.02$30,040.00View SEC Filing  
12/1/2015Alan C. HermaninsiderSell11,333$29.49$334,210.17View SEC Filing  
11/13/2015Christos RichardsDirectorSell15,000$27.49$412,350.00View SEC Filing  
11/2/2015Alan C. HermaninsiderSell18,416$28.71$528,723.36View SEC Filing  
10/1/2015Alan C. HermaninsiderSell4,250$18.98$80,665.00View SEC Filing  
9/1/2015Alan C. HermaninsiderSell11,333$27.39$310,410.87View SEC Filing  
8/18/2015Mats WahlstromDirectorSell6,373$33.50$213,495.50View SEC Filing  
8/17/2015Mats WahlstromDirectorSell8,028$33.91$272,229.48View SEC Filing  
8/14/2015Mats WahlstromDirectorSell116,554$34.24$3,990,808.96View SEC Filing  
6/15/2015August J TroendleDirectorSell250,000$26.68$6,670,000.00View SEC Filing  
11/12/2014Eli & Co LillyInsiderBuy164,963$13.50$2,227,000.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Coherus BioSciences (NASDAQ CHRS)

Source:
DateHeadline
Stock Traders Purchase Large Volume of Put Options on Coherus BioSciences (CHRS)Stock Traders Purchase Large Volume of Put Options on Coherus BioSciences (CHRS)
www.americanbankingnews.com - November 23 at 1:36 AM
-$0.90 EPS Expected for Coherus BioSciences, Inc. (CHRS) This Quarter-$0.90 EPS Expected for Coherus BioSciences, Inc. (CHRS) This Quarter
www.americanbankingnews.com - November 18 at 9:14 AM
Trade of the Day: Coherus Biosciences Inc (CHRS) - Investorplace.comTrade of the Day: Coherus Biosciences Inc (CHRS) - Investorplace.com
investorplace.com - November 17 at 2:24 PM
ValuEngine Lowers Coherus BioSciences, Inc. (CHRS) to Strong SellValuEngine Lowers Coherus BioSciences, Inc. (CHRS) to Strong Sell
www.americanbankingnews.com - November 11 at 7:00 PM
Coherus BioSciences Reports Third Quarter 2017 Operating and Financial Results - GlobeNewswire (press release)Coherus BioSciences Reports Third Quarter 2017 Operating and Financial Results - GlobeNewswire (press release)
globenewswire.com - November 7 at 8:13 PM
Edited Transcript of CHRS earnings conference call or presentation 6-Nov-17 9:30pm GMTEdited Transcript of CHRS earnings conference call or presentation 6-Nov-17 9:30pm GMT
finance.yahoo.com - November 7 at 8:12 PM
Coherus BioSciences, Inc. (CHRS) Releases  Earnings ResultsCoherus BioSciences, Inc. (CHRS) Releases Earnings Results
www.americanbankingnews.com - November 7 at 10:09 AM
Coherus BioSciences Reports Third Quarter 2017 Operating and Financial ResultsCoherus BioSciences Reports Third Quarter 2017 Operating and Financial Results
finance.yahoo.com - November 6 at 6:22 PM
Coherus BioSciences reports 3Q lossCoherus BioSciences reports 3Q loss
finance.yahoo.com - November 6 at 6:22 PM
Coherus BioSciences, Inc. (CHRS) Receives Average Rating of "Buy" from AnalystsCoherus BioSciences, Inc. (CHRS) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - November 6 at 3:58 PM
Coherus BioSciences Management to Present at Credit Suisse Scottsdale Healthcare Conference - GlobeNewswire (press release)Coherus BioSciences Management to Present at Credit Suisse Scottsdale Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - November 1 at 5:57 PM
Coherus BioSciences Management to Present at Credit Suisse Scottsdale Healthcare ConferenceCoherus BioSciences Management to Present at Credit Suisse Scottsdale Healthcare Conference
finance.yahoo.com - November 1 at 5:57 PM
Coherus BioSciences, Inc. (CHRS) Scheduled to Post Quarterly Earnings on TuesdayCoherus BioSciences, Inc. (CHRS) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:08 AM
-$1.05 Earnings Per Share Expected for Coherus BioSciences, Inc. (CHRS) This Quarter-$1.05 Earnings Per Share Expected for Coherus BioSciences, Inc. (CHRS) This Quarter
www.americanbankingnews.com - October 28 at 7:28 PM
Coherus BioSciences Is Now Oversold (CHRS)Coherus BioSciences Is Now Oversold (CHRS)
www.thestreet.com - October 26 at 5:26 PM
Coherus BioSciences, Inc. breached its 50 day moving average in a Bearish Manner : CHRS-US : October 24, 2017Coherus BioSciences, Inc. breached its 50 day moving average in a Bearish Manner : CHRS-US : October 24, 2017
finance.yahoo.com - October 24 at 7:32 PM
Coherus BioSciences to Report Third Quarter 2017 Financial Results on November 6th - GlobeNewswire (press release)Coherus BioSciences to Report Third Quarter 2017 Financial Results on November 6th - GlobeNewswire (press release)
globenewswire.com - October 23 at 5:46 PM
Coherus BioSciences to Report Third Quarter 2017 Financial Results on November 6thCoherus BioSciences to Report Third Quarter 2017 Financial Results on November 6th
finance.yahoo.com - October 23 at 5:46 PM
ETFs with exposure to Coherus BioSciences, Inc. : October 20, 2017ETFs with exposure to Coherus BioSciences, Inc. : October 20, 2017
finance.yahoo.com - October 20 at 3:37 PM
Breakfast Technical Briefing on Biotech Stocks -- Coherus Biosciences, Exelixis, Geron, and Grifols - PR Newswire (press release)Breakfast Technical Briefing on Biotech Stocks -- Coherus Biosciences, Exelixis, Geron, and Grifols - PR Newswire (press release)
www.prnewswire.com - October 19 at 3:59 PM
Coherus BioSciences, Inc. (CHRS) Given Consensus Rating of "Buy" by BrokeragesCoherus BioSciences, Inc. (CHRS) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 12 at 5:04 PM
ETFs with exposure to Coherus BioSciences, Inc. : October 9, 2017ETFs with exposure to Coherus BioSciences, Inc. : October 9, 2017
finance.yahoo.com - October 9 at 5:51 PM
Coherus BioSciences, Inc. :CHRS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017Coherus BioSciences, Inc. :CHRS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 6 at 5:25 PM
Coherus BioSciences, Inc. (CHRS) Receives "Outperform" Rating from Credit Suisse GroupCoherus BioSciences, Inc. (CHRS) Receives "Outperform" Rating from Credit Suisse Group
www.americanbankingnews.com - September 27 at 9:28 AM
UBS Downgrades AbbVie; Heres What Changed Analysts View - BenzingaUBS Downgrades AbbVie; Here's What Changed Analysts' View - Benzinga
www.benzinga.com - September 25 at 3:31 PM
First Week Of May 2018 Options Trading For Coherus BioSciences (CHRS)First Week Of May 2018 Options Trading For Coherus BioSciences (CHRS)
www.thestreet.com - September 25 at 12:35 PM
UBS Downgrades AbbVie; Heres What Changed Analysts ViewUBS Downgrades AbbVie; Here's What Changed Analysts' View
finance.yahoo.com - September 25 at 12:35 PM
Coherus BioSciences, Inc. (CHRS) Given Consensus Recommendation of "Buy" by AnalystsCoherus BioSciences, Inc. (CHRS) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 17 at 12:54 PM
Reviewing Coherus BioSciences (CHRS) & Zafgen (ZFGN)Reviewing Coherus BioSciences (CHRS) & Zafgen (ZFGN)
www.americanbankingnews.com - September 14 at 12:24 PM
Head to Head Review: Coherus BioSciences (CHRS) and Its RivalsHead to Head Review: Coherus BioSciences (CHRS) and Its Rivals
www.americanbankingnews.com - September 13 at 4:30 PM
3 Stocks With McDonald's-Like Return Potential3 Stocks With McDonald's-Like Return Potential
finance.yahoo.com - September 11 at 10:51 PM
Coherus BioSciences, Inc. breached its 50 day moving average in a Bearish Manner : CHRS-US : September 11, 2017Coherus BioSciences, Inc. breached its 50 day moving average in a Bearish Manner : CHRS-US : September 11, 2017
finance.yahoo.com - September 11 at 5:50 PM
Coherus BioSciences Provides Update on 619 IPR Institution Decision - GlobeNewswire (press release)Coherus BioSciences Provides Update on '619 IPR Institution Decision - GlobeNewswire (press release)
globenewswire.com - September 8 at 10:35 PM
Coherus BioSciences (CHRS) Outperform Rating Reiterated at Cowen and CompanyCoherus BioSciences' (CHRS) Outperform Rating Reiterated at Cowen and Company
www.americanbankingnews.com - September 8 at 9:52 PM
Coherus BioSciences, Inc. (CHRS) Earns Buy Rating from Maxim GroupCoherus BioSciences, Inc. (CHRS) Earns Buy Rating from Maxim Group
www.americanbankingnews.com - September 8 at 8:21 AM
Coherus BioSciences Provides Update on ‘619 IPR Institution DecisionCoherus BioSciences Provides Update on ‘619 IPR Institution Decision
finance.yahoo.com - September 7 at 5:19 PM
Coherus BioSciences Management to Present at Three Investor Healthcare Conferences in September - GlobeNewswire (press release)Coherus BioSciences Management to Present at Three Investor Healthcare Conferences in September - GlobeNewswire (press release)
globenewswire.com - September 1 at 10:29 PM
Coherus BioSciences Management to Present at Three Investor Healthcare Conferences in SeptemberCoherus BioSciences Management to Present at Three Investor Healthcare Conferences in September
finance.yahoo.com - September 1 at 5:26 PM
Coherus BioSciences, Inc. – Value Analysis (NASDAQ:CHRS) : August 30, 2017Coherus BioSciences, Inc. – Value Analysis (NASDAQ:CHRS) : August 30, 2017
finance.yahoo.com - August 29 at 10:38 PM
Coherus BioSciences (CHRS) Reports Positive Topline Results for Clinical Pharmacokinetic Bioequivalence Study for ... - StreetInsider.comCoherus BioSciences (CHRS) Reports Positive Topline Results for Clinical Pharmacokinetic Bioequivalence Study for ... - StreetInsider.com
www.streetinsider.com - August 28 at 10:08 PM
Coherus BioSciences (CHRS) Reports Positive Topline Results for Clinical ...Coherus BioSciences (CHRS) Reports Positive Topline Results for Clinical ...
www.streetinsider.com - August 28 at 5:07 PM
Coherus Announces Results For Pharmacokinetic Bioequivalence Study For CHS-1420Coherus Announces Results For Pharmacokinetic Bioequivalence Study For CHS-1420
www.rttnews.com - August 28 at 5:07 PM
Coherus BioSciences Announces Positive Topline Results for Clinical ...Coherus BioSciences Announces Positive Topline Results for Clinical ...
www.nasdaq.com - August 28 at 5:07 PM
Coherus BioSciences Announces Positive Topline Results for Clinical Pharmacokinetic Bioequivalence Study for CHS-1420 (Humira® Biosimilar Candidate) versus European Marketed Humira in Healthy SubjectsCoherus BioSciences Announces Positive Topline Results for Clinical Pharmacokinetic Bioequivalence Study for CHS-1420 (Humira® Biosimilar Candidate) versus European Marketed Humira in Healthy Subjects
finance.yahoo.com - August 28 at 5:07 PM
Coherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US : August 23, 2017Coherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US : August 23, 2017
finance.yahoo.com - August 23 at 5:35 PM
Coherus BioSciences, Inc. (CHRS) Receives Consensus Recommendation of "Buy" from AnalystsCoherus BioSciences, Inc. (CHRS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 23 at 2:34 PM
Coherus BioSciences (CHRS) to Raise Up to $150M in from Temasek in Two TranchesCoherus BioSciences (CHRS) to Raise Up to $150M in from Temasek in Two Tranches
www.streetinsider.com - August 21 at 5:02 PM
Coherus Secures Private Placement from TemasekCoherus Secures Private Placement from Temasek
finance.yahoo.com - August 21 at 5:02 PM
Coherus Bio Jumps on Private PlacementCoherus Bio Jumps on Private Placement
finance.yahoo.com - August 21 at 5:02 PM
Coherus BioSciences, Inc. (CHRS) Insider Alan C. Herman Sells 17,535 SharesCoherus BioSciences, Inc. (CHRS) Insider Alan C. Herman Sells 17,535 Shares
www.americanbankingnews.com - August 10 at 8:02 PM

Social Media

Financials

Chart

Coherus BioSciences (NASDAQ CHRS) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.